New York, Jan 5, 2026, 18:23 EST — After-hours
- UnitedHealth shares ended up 1.7% on Monday, outperforming as managed-care names rose broadly
- Barclays lifted its UnitedHealth price target to $391 and kept an Overweight rating
- Investors are positioning ahead of UnitedHealth’s Jan. 27 results and 2026 guidance
UnitedHealth Group Inc (UNH.N) shares rose 1.7% on Monday to $342.02, after Barclays lifted its price target on the insurer.
The move matters because UnitedHealth has been a re-rating story: the stock remains far below its 52-week high and investors are looking for signs that 2026 margins can stabilize. UnitedHealth’s 52-week range is $234.60 to $606.36, underscoring how quickly sentiment has swung in the group.
The next hard catalyst is earnings. UnitedHealth said it will release full-year 2025 results and provide 2026 financial guidance on Jan. 27 before the market opens, with a conference call scheduled for 8 a.m. ET.
Barclays analyst Andrew Mok raised the firm’s price target on UnitedHealth to $391 from $386 and reiterated an Overweight rating, a call that signals the stock should be held in greater size than a benchmark allocation. Mok pointed to rotation toward “de-rated underperformers” as investors look for margin expansion in managed-care stocks, a term for insurers that administer health plans and manage medical costs. TipRanks
UnitedHealth’s rise came alongside gains across large U.S. health insurers, with Humana, Elevance and Cigna also higher in a session when the S&P 500 and Dow ended in the green.
The backdrop remains execution. UnitedHealth said in December it would implement operational changes after external reviews of parts of its health services and pharmacy benefit units, aiming to standardize processes and increase automation.
For investors, the earnings call is expected to hinge on two questions: what management sees in medical-cost trends and whether Optum and UnitedHealthcare can deliver steadier profitability in 2026. Health insurers’ margins can tighten quickly when claims rise faster than premiums.
Monday’s trade showed buyers stepping in on dips, with the stock ranging between $333.86 and $346.83 during the session on about 7.9 million shares.
But a target hike does not settle the debate: if utilization stays elevated or pricing lags cost growth, UnitedHealth’s 2026 outlook could disappoint and pressure the stock again, particularly given the sharp distance from last year’s highs.
What markets watch next is the January macro drumbeat — including the U.S. employment report for December due Jan. 9 — and then UnitedHealth’s Jan. 27 guidance update, which lands as the Federal Reserve begins its Jan. 27–28 policy meeting.
